Molecular Characterization of NoxA1 in VSMC NADPH Oxidase Activation
VSMC NADPH 氧化酶激活中 NoxA1 的分子表征
基本信息
- 批准号:8373377
- 负责人:
- 金额:$ 43.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-20 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAngioplastyAnimal ModelAortaApolipoprotein EArterial Fatty StreakArterial InjuryArteriesAtherosclerosisAttenuatedBlood PressureBlood VesselsCardiacCardiovascular DiseasesCarotid ArteriesCatalytic DomainCell CommunicationCell Culture TechniquesCell LineComplementCytochromes bDataDiseaseDissectionElectronsEndotheliumEnzymesEventExhibitsFamilyFunctional disorderGene ExpressionGenerationsGeneticGoalsGrowthGrowth FactorHomologous GeneHumanHyperplasiaHypertensionInfectionInflammatoryK-562LaboratoriesLeadLeukocytesLipidsMedialMembraneMethodologyMolecularMusMutationNADPNADPH OxidaseOxidasesOxidation-ReductionOxidative StressOxygenPhosphorylationPhosphorylation SitePlasmaPlayPost-Translational Protein ProcessingProductionProtein KinaseReactive Oxygen SpeciesReagentRegulationResearchRespiratory BurstRodentRoleSerineSignal TransductionSmooth Muscle MyocytesStimulusStrokeStructureSuperoxidesTherapeuticTimeTunica AdventitiaVascular DiseasesVascular ProliferationVentricular Functionatherogenesisattenuationbasedeletion analysisgenetic regulatory proteinhuman CYBA proteinin vivoinhibitor/antagonistinjuredinsightmemberneointima formationneutrophil cytosol factor 40Kneutrophil cytosol factor 67Knovelnovel strategiesoverexpressionprotein protein interactionresponserestenosissmall hairpin RNAsmall molecule librariestranscription factorvascular smooth muscle cell proliferation
项目摘要
DESCRIPTION (provided by applicant): Extensive evidence from animal models and human studies supports the hypothesis that NADPH oxidase derived oxidative stress is a major contributor to the pathophysiology of cardiovascular diseases. In particular, dysregulation of Nox1 NADPH oxidase has been implicated in many vascular diseases including atherosclerosis, aortic dissection, hypertension and stroke. Although molecular mechanisms activating the Nox2 (gp91phox) NADPH oxidase have been elucidated, the events that lead to dysregulation of Nox1 NADPH oxidase activity are not well understood. Our prior studies and preliminary data support the notion that NoxA1, the homologue of p67phox, is expressed in mouse and human vascular smooth muscle cells (VSMC) and is a key regulator of Nox1 NADPH oxidase activity. NoxA1-dependent reactive oxygen species (ROS) play an essential role in agonist-induced VSMC proliferation and growth-promoting, redox-sensitive protein kinase activation. NoxA1 is upregulated in aortas and atherosclerotic lesions of ApoE-/- mice and in intimal and medial VSMC of human early carotid atherosclerotic lesions. In this proposal we will investigate how NoxA1 and p47phox interaction regulates Nox1 NADPH oxidase activity in VSMC, the mechanisms that regulate NoxA1 expression and post translational modifications and their role in Nox1 NADPH oxidase activation. We will also determine the role of NoxA1-dependent ROS production in restenosis and atherosclerosis. We will screen a small molecule library to identify potential inhibitors of Nox1 NADPH oxidase activity to complement the genetic approaches. To accomplish these goals, we have assembled a unique set of reagents and methodologies including NoxA1-/-, ApoE-/-/NoxA1-/- and [SM22α-CreKI/+/NoxA1f/+] mice, Nox1y/-, p47phox-/- and NoxA1-/- mouse aortic VSMC cultures, adenoviral NoxA1 overexpression and shRNA constructs and a functional AlphaScreen and a 100,000 member library of small molecules for identifying potential Nox1 NADPH oxidase inhibitors. Our research strategy includes the following three specific aims. Aim 1: Define the molecular mechanisms of NoxA1-dependent NADPH oxidase activity in agonist-induced ROS generation in mouse and human aortic VSMC. Aim 2: Determine the effect of NoxA1 deficiency in restenosis and atherosclerosis. Aim 3: Identify novel and specific NoxA1 and p47phox interaction inhibitors as means to regulating Nox1 activity. Together, these studies will establis the role of VSMC Nox1 NADPH oxidase in vascular pathophysiology and potentially identify strategies/compounds for the regulation of this enzyme.
PUBLIC HEALTH RELEVANCE: Oxidative stress generated from dysregulated Nox1 NADPH oxidase activity has been implicated in a growing number of vascular diseases including atherosclerosis, aortic dissection, hypertension and stroke. Elucidation of molecular composition and activation mechanisms of this VSMC NADPH oxidase will yield valuable insight to develop novel approaches for the treatment of various oxidative stress-dependent vascular diseases.
描述(由申请人提供):来自动物模型和人体研究的大量证据支持NADPH氧化酶衍生的氧化应激是心血管疾病病理生理的主要因素这一假设。特别是,Nox1 NADPH氧化酶的失调与许多血管疾病有关,包括动脉粥样硬化、主动脉夹层、高血压和中风。虽然已经阐明了激活Nox2 (gp91phox) NADPH氧化酶的分子机制,但导致Nox1 NADPH氧化酶活性失调的事件尚不清楚。我们之前的研究和初步数据支持这样的观点,即p67phox的同源物NoxA1在小鼠和人类血管平滑肌细胞(VSMC)中表达,并且是Nox1 NADPH氧化酶活性的关键调节因子。noxa1依赖性活性氧(ROS)在激动剂诱导的VSMC增殖和促生长、氧化还原敏感蛋白激酶激活中发挥重要作用。NoxA1在ApoE-/-小鼠的主动脉和动脉粥样硬化病变以及人类早期颈动脉粥样硬化病变的内膜和内侧VSMC中表达上调。在本文中,我们将研究NoxA1和p47phox相互作用如何调节VSMC中Nox1 NADPH氧化酶的活性,以及NoxA1表达和翻译后修饰的调节机制及其在Nox1 NADPH氧化酶激活中的作用。我们还将确定noxa1依赖性ROS产生在再狭窄和动脉粥样硬化中的作用。我们将筛选一个小分子文库,以确定Nox1 NADPH氧化酶活性的潜在抑制剂,以补充遗传方法。为了实现这些目标,我们已经组装了一套独特的试剂和方法,包括NoxA1-/-, ApoE-/-/NoxA1-/-和[SM22α;- creki /+/NoxA1 -/-和[SM22α;]小鼠,NoxA1 /-, p47phox-/-和NoxA1-/-小鼠主动脉VSMC培养,腺病毒NoxA1过表达和shRNA构建,功能性AlphaScreen和100,000成员的小分子文库,用于鉴定潜在的Nox1 NADPH氧化酶抑制剂。我们的研究策略包括以下三个具体目标。目的1:明确noxa1依赖性NADPH氧化酶活性在激动剂诱导小鼠和人主动脉VSMC中ROS生成的分子机制。目的2:确定NoxA1缺乏对再狭窄和动脉粥样硬化的影响。目的3:鉴定新的特异性NoxA1和p47phox相互作用抑制剂,作为调节Nox1活性的手段。总之,这些研究将确定VSMC Nox1 NADPH氧化酶在血管病理生理中的作用,并可能确定该酶的调节策略/化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARSCHALL S. RUNGE其他文献
MARSCHALL S. RUNGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARSCHALL S. RUNGE', 18)}}的其他基金
North Carolina Translational & Clinical Sciences Institute (NC TraCS)
北卡罗来纳州翻译
- 批准号:
8721094 - 财政年份:2013
- 资助金额:
$ 43.29万 - 项目类别:
North Carolina Translational & Clinical Sciences Institute (NC TraCS)
北卡罗来纳州翻译
- 批准号:
8721100 - 财政年份:2013
- 资助金额:
$ 43.29万 - 项目类别:
North Carolina Translational & Clinical Sciences Institute (NC TraCS)
北卡罗来纳州翻译
- 批准号:
8721096 - 财政年份:2013
- 资助金额:
$ 43.29万 - 项目类别:
North Carolina Translational & Clinical Sciences Institute (NC TraCS)
北卡罗来纳州翻译
- 批准号:
8917646 - 财政年份:2013
- 资助金额:
$ 43.29万 - 项目类别:
Molecular Characterization of NoxA1 in VSMC NADPH Oxidase Activation
VSMC NADPH 氧化酶激活中 NoxA1 的分子表征
- 批准号:
8514712 - 财政年份:2012
- 资助金额:
$ 43.29万 - 项目类别:
Molecular Characterization of NoxA1 in VSMC NADPH Oxidase Activation
VSMC NADPH 氧化酶激活中 NoxA1 的分子表征
- 批准号:
8661272 - 财政年份:2012
- 资助金额:
$ 43.29万 - 项目类别:
Molecular Characterization of NoxA1 in VSMC NADPH Oxidase Activation
VSMC NADPH 氧化酶激活中 NoxA1 的分子表征
- 批准号:
8845598 - 财政年份:2012
- 资助金额:
$ 43.29万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 43.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 43.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 43.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)